UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~April~~June 2817, 2022

ABIOMED, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-09585	04-2743260
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

22 Cherry Hill Drive
Danvers, Massachusetts 01923

(Address of Principal Executive Offices, including Zip Code)

(978) 646-1400

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol	Name of each exchange on which registered
Common Stock, $0.01 par value	ABMD	The NASDAQ Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 28.0201 ~~Results~~Other ~~of Operations and Financial Condition~~Events.

OnIn ~~April~~August 282019, ~~2022, ABIOMED, Inc. (~~the “Company,” ~~“we”~~announced orthat ~~“us”)~~its ~~issued~~Board aof ~~press~~Directors ~~release~~had ~~reporting~~authorized ~~our~~the ~~financial~~repurchase ~~results~~of ~~for~~up ~~our~~to ~~fourth~~$200 ~~quarter~~million ~~and~~of ~~fiscal~~the ~~year~~Company’s ~~ended~~common ~~March~~stock. ~~31,~~Under ~~2022.~~this Astock ~~copy~~repurchase ofprogram (“the ~~press~~Program”), ~~release~~the Company is ~~set~~authorized ~~forth~~to asrepurchase ~~Exhibit~~shares ~~99.1~~through ~~and~~open ismarket ~~incorporated~~purchases, ~~herein~~privately-negotiated bytransactions ~~reference.~~or ~~The~~otherwise ~~information~~in ~~contained~~accordance inwith ~~this~~applicable ~~report~~federal ~~shall~~securities ~~not~~laws, beincluding ~~deemed~~through ~~"filed"~~Rule ~~for~~10b5-1 ~~purposes~~trading ofplans ~~Section~~and under Rule 10b-18 of the Securities Exchange Act of 1934. orThe ~~otherwise~~Program ~~subject~~has tono ~~the~~expiration ~~liabilities~~date ofand ~~that~~may ~~Section,~~be ~~nor~~suspended ~~shall~~for itperiods beor ~~deemed~~discontinued ~~incorporated~~at byany ~~reference~~time. inThe ~~any~~Company ~~filing~~most ~~under~~recently ~~the~~repurchased ~~Securities~~shares ~~Act~~ of ~~1933~~its orcommon ~~the~~stock ~~Securities~~pursuant ~~Exchange~~to ~~Act~~a of10b5-1 ~~1934,~~plan ~~whether~~which ~~made~~expired ~~before~~on orJune ~~after~~30, ~~the~~2020. ~~date~~Effective ~~hereof~~June ~~and~~17, ~~regardless~~2022, ofthe ~~any~~Company ~~general~~entered ~~incorporation~~into ~~language~~a innew ~~such~~10b5-1 ~~filing,~~plan ~~except~~to ascontinue ~~expressly~~repurchases ~~set~~of ~~forth~~the byCompany’s ~~specific~~common ~~reference~~stock inunder ~~such~~the ~~filing~~Program.

Caution Concerning Forward-Looking Statements

This Form 8-K contains information that includes or is based on forward-looking statements within the meaning of the federal securities laws that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such statements include, but are not limited to, those regarding our financial performance and the impact of the COVID-19 pandemic on our operations and financial results and are subject to, among other risks, the COVID-19 pandemic and any related policies and actions by governments or other third parties. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit		Description
99.1		Press release dated April 28, 2022
104		Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ABIOMED, Inc.
	By:	/s/ ~~Todd~~Marc A. ~~Trapp~~Began
		Todd A. TrappVice President and Chief Financial Officer(Authorized Signatory)
		Marc A. BeganVice President, General Counsel and Secretary
Date: April 28, 2022
Date: June 21, 2022

Filing Compare · ABIOMED INC